Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes and subsequently approved for chronic weight management. It mimics the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake. Clinical trials (STEP and SUSTAIN programs) have demonstrated average weight loss of 15-17% of body weight over 68 weeks. It is available as a once-weekly subcutaneous injection or daily oral tablet.
Extensive clinical evidence
Well-tolerated with minimal side effects
How It Works
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, enhances insulin secretion, and suppresses glucagon release.
Key Benefits
- Significant and sustained weight loss
- Improved glycemic control and HbA1c reduction
- Reduced cardiovascular risk in diabetic patients
- Decreased appetite and food cravings
- Improved blood pressure and lipid profiles
- Potential neuroprotective effects under investigation
Who May Benefit
- Individuals with obesity (BMI 30+) or overweight with comorbidities
- People with type 2 diabetes
- Those who struggled with diet and exercise alone
- Patients seeking medically supervised weight management
Dosage & Administration
Expected Timeline
Appetite reduction in 1-2 weeks. Meaningful weight loss by 12-16 weeks. Average 14.9% loss over 68 weeks.
Safety Information
Possible Side Effects
Contraindications
Dr. Taylor's 2 Cents
“Semaglutide is the most well-studied peptide on this list, period. The STEP trials are gold-standard evidence — 15-17% body weight loss sustained over years. As someone who lost over 100 lbs after Cushing's syndrome, I deeply understand the metabolic challenges of weight loss. GLP-1 agonists are game-changers, but they require medical supervision for dose titration and monitoring. The GI side effects are real but manageable with proper protocol.”
Discuss with Dr. Taylor →Frequently Asked Questions
How much weight can I lose?
How is it administered?
What are common side effects?
Is Semaglutide FDA approved?
Do I need to diet?
What happens when I stop?
How does it compare to Tirzepatide?
Published Research
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021)
Key Finding: Semaglutide 2.4 mg produced a mean 14.9% body weight loss over 68 weeks vs 2.4% with placebo; 86% of participants achieved at least 5% weight loss.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino D, Abrahamsson N, Davies M, et al. · JAMA (2021)
Key Finding: Participants continuing semaglutide achieved total weight reduction of 17.4%, while those switched to placebo regained weight, demonstrating ongoing treatment sustains results.
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Lingvay I, Brown-Frandsen K, Colhoun HM, et al. · Nature Medicine (2024)
Key Finding: Semaglutide produced weight loss sustained for up to 4 years, with a mean reduction of 10.2% at 208 weeks and 12% of patients achieving normal weight status.
Protocols Featuring Semaglutide
Related Peptides
Related Reading
Want personalized guidance?
Consult with Dr. Patrick Taylor for a comprehensive evaluation and personalized protocol.
Book a ConsultationMedical Disclaimer: This information is for educational purposes only and is not medical advice. Consult a healthcare provider before starting any peptide protocol.